Navigating the challenges of colorectal cancer screening

Exact Sciences is uniquely positioned to support your efforts with a CRC screening solution backed by an understanding of health systems' needs and priorities.
Physician roundtable meeting.

Connect with us

Explore how we can support your health system’s efforts to improve CRC screening rates.
Closing the colorectal cancer (CRC) screening gap is critical to improve quality measures, provide better outcomes, and enhance the patient experience. With many health systems facing challenges meeting CRC screening goals, it's time to consider a company with a strong history of collaborating with health systems to develop multidisciplinary, standardized, and scalable CRC screening solutions.
CRC screening rates by demographic indicators.

An estimated 60 million Americans are due for CRC screening3

CRC remains “the most preventable, yet least prevented, cancer.”4 National CRC screening rates remain well below established goals.1,2

Real-world experience

See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.
CRC treatment costs increase with each stage of diagnosis5
Costs per Medicare patient increases >3x from Stage I to Stage IV

Loading component...

Cologuard® first. Colonoscopy as needed.

For 10 years, the Cologuard test has set the standard for stool DNA-based testing in average-risk individuals aged 45 or older.16

Solutions from a partner that understands your business

There's more to CRC screening than just a test result. Exact Sciences offers:

Optimized workflows

Optimizing workflows to help achieve CRC screening goals and improve quality measure scores

Digital health infrastructure

Promoting efficiency by maximizing the capabilities of your digital health infrastructure

3 years of credits

Offering the only guideline-recommended noninvasive CRC screening test applicable for 3 years of Healthcare Effectiveness Data and Information Set (HEDIS®) credits17-19,‖¶
Connect with us
Explore how we can support your health system's goals for improving CRC screening rates.

Important Information about the Cologuard products


Indications for Use

The Cologuard® and Cologuard Plus® tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Contraindications

The Cologuard products are not for high-risk individuals, including patients who have the following:

  • a personal history of colorectal cancer or precancerous colon polyps​
  • a positive result from another colorectal cancer screening method within that test's recommended screening interval​
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as inflammatory bowel disease (IBD), chronic ulcerative colitis (UC), Crohn’s disease
  • have a first-degree family history of colorectal cancer, or certain hereditary syndromes

Patients should talk to a healthcare provider if any of these situations apply.


Warnings and Precautions

All positive results should be referred to colonoscopy.

The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.

A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.

Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.

Rx only.